Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report
Keywords:Brain metastases, Central nervous system, KRAS, NSCLC, Sotorasib
In the CodeBreaK 100 phase 2 study, sotorasib was active for patients with metastatic non-small cell lung cancer (NSCLC) harboring Kirsten rat sarcoma viral oncogene homologue (KRAS) p.G12C mutation. However, patients with untreated and/or active brain metastases were excluded from the trial, and the activity of sotorasib in the setting of brain metastases should be further investigated. Here we report the case of a KRAS p.G12C mutant NSCLC patient with three brain metastases, of whom one was untreated and the other two had progressed after radiotherapy with symptoms requiring steroids, that responded to sotorasib. Our report suggests that sotorasib may be active against untreated or progressive brain metastases, supporting further evaluation of sotorasib in this setting.
Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398(10299):535-554. https://doi.org/10.1016/S0140-6736(21)00312-3 PMID:34273294 DOI: https://doi.org/10.1016/S0140-6736(21)00312-3
Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384(25):2371-2381. https://doi.org/10.1056/NEJMoa2103695 PMID:34096690 DOI: https://doi.org/10.1056/NEJMoa2103695
Inno A, Di Noia V, D’Argento E, Modena A, Gori S. State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer. Transl Lung Cancer Res. 2016;5(6):599-609. https://doi.org/10.21037/tlcr.2016.11.01 PMID:28149755 DOI: https://doi.org/10.21037/tlcr.2016.11.01
Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2018;JCO2018783118(33):JCO2018783118. https://doi.org/10.1200/JCO.2018.78.3118 PMID:30153097 DOI: https://doi.org/10.1200/JCO.2018.78.3118
Gadgeel S, Peters S, Mok T, et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol. 2018;29(11):2214-2222. https://doi.org/10.1093/annonc/mdy405 PMID:30215676 DOI: https://doi.org/10.1093/annonc/mdy405
Lamberti G, Aizer A, Ricciuti B, et al. Incidence of brain metastases and preliminary evidence of intracranial activity with sotorasib in patients with KRASG12C-mutant non-small-cell lung cancer. JCO Precis Oncol. 2023;7(7):e2200621. https://doi.org/10.1200/PO.22.00621 PMID:36809054 DOI: https://doi.org/10.1200/PO.22.00621
How to Cite
Copyright (c) 2023 The Authors
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors contributing to Drug Target Insights agree to publish their articles under the Creative Common Attribution Non Commercial 4.0 (CC-BY-NC 4.0) license, which allows third parties to re-use the work without permission as long as the work is properly referenced and the use is non-commercial.